The following highlights key information for immunization providers. Please refer to the remainder of this supplemental statement for details.
1. What
Supemtek™ is a quadrivalent recombinant seasonal influenza vaccine (RIV4) that has recently been authorized for use in Canada in adults 18 years of age and older. Supemtek is the first and, to date, the only seasonal influenza vaccine made with recombinant technology available in Canada. Other influenza vaccines are made in eggs or mammalian cell cultures.
2. Who
This supplemental statement addresses the annual influenza vaccination of adults who do not have contraindications to Supemtek.
3. How
Supemtek may be considered among the quadrivalent influenza vaccines offered to adults 18 years of age and older for their annual influenza vaccination.
4. Why
Supemtek is considered effective, immunogenic, and safe in adults 18 years of age and older and has a comparable immunogenicity and safety profile to egg- and cell culture-based, inactivated, live attenuated, adjuvanted, and high-dose seasonal influenza vaccines already licensed in Canada. Supemtek can provide a broader protection against influenza when compared to trivalent vaccines as its formulation contains both influenza B lineages. In addition, it contains identical hemagglutinin proteins to target influenza strains.
- Recommendation
- Americas
- Canada
- Influenza
